Researchers at the Pharmacy Department of the CEU Cardenal Herrera University published the design of the new bioadhesive ocular insert in the international journal Drug Delivery and Translational Research. Credit: Asociación RUVID.

Researchers at the CEU Cardenal Herrera University (CEU UCH) in Spain have unveiled the design of a new bioadhesive ocular insert that can release a high volume of medicine through the cornea of the eye in a controlled manner.

Intended to be placed inside the eyelid, the new product provides an effective alternative to existing application approaches that are said to result in a limited release of creams or drops.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new insert has been specifically designed to deliver antibiotic moxifloxacin, which is commonly used to treat bacterial infections of the eyes, including corneal queratitis and bacterial endophthalmitis.

A statement by the researchers read: “When we apply cream or drops in the eyes, eyeball defence mechanisms such as tears are triggered, which dilutes the applied medicine. Sometimes, less than 5% of the medicine administered in this way manages to penetrate the eye in an effective way.

“Therefore, pharmaceutical research aims to develop ocular inserts, very thin cylinders or discs made of bioadhesive polymeric materials, which adapt to the shape of the eye and release the medicine through the cornea in a controlled manner.”

“The new insert has been specifically designed to deliver antibiotic moxifloxacin, which is commonly used to treat bacterial infections of the eyes.”

The team developed, tested and compared various kinds of inserts using bioadhesive polymers of different physicochemical characteristics to determine the one with an optimal degree of permeability for carrying moxifloxacin.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

They selected an insert that was thin, practically transparent and could easily stick to the ocular mucosa.

The team added: “The ocular release of moxifloxacin with this insert would make for an improved treatment of some ocular illnesses such as bacterial endophthalmitis, an infection of the eyeball, which can appear after suffering a wound or as a complication following intraocular surgery.

“It can also be used for treating corneal queratitis, an infection of the cornea, which causes inflammation and can leave a leucoma or scar as a result.”

Furthermore, the researchers plan to work towards applying the approach to other medicines.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact